Journal of Medicinal Chemistry · 2023 · 31 citations · 36 references
MedicinePharmaceuticsPharmacologyDrug DeliveryMolecular ImagingTargeted Drug DeliveryCancer NanomedicineRadiopharmaceutical DesignTargeted Cancer TherapyTargeted Radionuclide TherapyTumor ImagingTumor Receptor ImagingCopper-64 ChemistryCopper-64 RadiopharmaceuticalsHigh-purity ProductionIntegrin BindingPeptide ConjugatesPeptide-drug ConjugatesReceptorsTherapeutic Efficacy Assessment
High Resolution Image Download MS PowerPoint Slide Many anticancer drugs exhibit high systemic off-target toxicities causing severe side effects. Peptide–drug conjugates (PDCs) that target tumor-specific receptors such as integrin α v β 6 are emerging as powerful tools to overcome these challenges. The development of an integrin α v β 6 -selective PDC was achieved by combining the therapeutic efficacy of the cytotoxic drug monomethyl auristatin E with the selectivity of the α v β 6 -binding peptide (α v β 6 -BP) and with the ability of positron emission tomography (PET) imaging by copper-64. The [ 64 Cu]PDC- 1 was produced efficiently and in high purity. The PDC exhibited high human serum stability, integrin α v β 6 -selective internalization, cell binding, and cytotoxicity. Integrin α v β 6 -selective tumor accumulation of the [ 64 Cu]PDC- 1 was visualized with PET-imaging and corroborated by biodistribution, and [ 64 Cu]PDC- 1 showed promising in vivo pharmacokinetics. The [ nat Cu]PDC- 1 treatment resulted in prolonged survival of mice bearing α v β 6 (+) tumors (median survival: 77 days, vs α v β 6 (−) tumor group 49 days, and all other control groups 37 days).
36
Rebecca L. Siegel, Kimberly D. Miller, Ahmedin Jemal · CA A Cancer Journal for Clinicians · 2019 · 21K citations · Full text
Malgorzata Barczyk, Sergio Carracedo, Donald Gullberg · Cell and Tissue Research · 2009 · 1.5K citations · Full text
Gene M. Dubowchik, Raymond A. Firestone, Linda Padilla et al. · Bioconjugate Chemistry · 2002 · 546 citations